Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61

Benzinga · 2d ago
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.